Canary Capital’s Staking-Enabled Injective ETF Receives Nasdaq Approval
Nasdaq approval for Canary Capital’s staking-enabled INJ ETF gives US investors a regulated route to Injective exposure and staking rewards.
Nasdaq approval for Canary Capital’s staking-enabled INJ ETF gives US investors a regulated route to Injective exposure and staking rewards. Injective (INJ) is trading at ₹772 ($8.17), up 1.2% since this brief published. This is an original Token Times brief synthesising 2 outlets (Bitcoin Sistemi, TronWeekly), plus live market data, as of Fri, 06 Nov 2026 09:45:01 UTC.
The approval introduces a listed ETF structure that combines exposure to INJ with staking rewards, potentially expanding access to the token’s staking utility. It also highlights Nasdaq’s willingness to consider crypto ETF products that include staking functionality.
- Canary Capital’s staking-enabled Injective ETF received Nasdaq approval.
- Bitcoin Sistemi reported an approximately 6% INJ rise after the announcement.
- TronWeekly highlighted regulated US exposure, staking rewards and Injective’s AI infrastructure ambitions.
- INJ trades at $8.07, down 4.02% over 24 hours but up 10.93% over seven days.
Bitcoin Sistemi and TronWeekly agree that Canary Capital’s Injective ETF received Nasdaq approval and will provide exposure to INJ with staking rewards. Bitcoin Sistemi emphasized the market reaction, reporting that INJ rose approximately 6% after the announcement, while TronWeekly focused on regulated access for US investors and staking rewards. The sources differ in emphasis rather than contradicting one another: TronWeekly additionally linked the development to Injective’s expansion into AI infrastructure, a detail absent from Bitcoin Sistemi’s summary.
- Nasdaq Approves Listing of Canary Capital’s Staked INJ ETF
- Canary Capital’s Staking-Enabled Injective ETF Receives Nasdaq Approval — this brief
Canary Capital’s staking-enabled 
Injective ETF has received Nasdaq approval, according to 
Bitcoin Sistemi and TronWeekly. The product is intended to give US investors regulated exposure to INJ while allowing them to receive staking rewards through an exchange-traded fund structure, a distinction highlighted by TronWeekly.
Bitcoin Sistemi reported that INJ gained approximately 6% following the Nasdaq announcement. The ETF combines access to the Injective token with staking functionality, potentially making participation in the network’s staking activity more accessible through a listed investment vehicle. TronWeekly framed the development around regulated US exposure rather than the short-term price reaction.
The two outlets corroborate the central approval and staking-enabled structure, but they emphasize different aspects of the story. Bitcoin Sistemi led with an approximately 6% increase in INJ, while TronWeekly stressed regulated investor access and staking rewards. TronWeekly also connected the ETF approval to Injective’s expansion into AI infrastructure, a point not included in the Bitcoin Sistemi summary.
The announcement came against a broadly weak crypto backdrop. Total crypto market capitalization is $2.61T, Bitcoin is down 5.78% over 24 hours, and the Fear & Greed index stands at 28, indicating a market mood classified as fear. By contrast, INJ is up 10.93% over seven days, while its live 24-hour move is down 4.02% at a price of $8.07. Its market capitalization is $806.59M.
The immediate developments to monitor are the ETF’s final Nasdaq listing arrangements and how its staking component will be implemented for investors. The reported post-announcement rise does not align with INJ’s current 24-hour performance, but its seven-day gain remains positive. With overall crypto sentiment still in fear territory and Bitcoin also lower, the ETF sits within a market backdrop of continued broad weakness.
Since this brief published about 3 hours ago, Injective (INJ) has moved from ₹762.91$8.07 to ₹772.37$8.17 — +1.24%.
The chart plots INJ's price: grey is the move before this brief published, the vertical dashed line marks the moment it published, the horizontal dashed line is the price then, and the coloured area is the move since — from Token Times's market data (daily resolution). It shows what happened after the news, not that the news caused it; many factors move prices. Not financial advice.
At today's peer-to-peer rate, 1 INJ ≈ ₹849.68 (about $8.17), down 3.9% over 24 hours. The rupee itself trades about 10.0% above the official rate on the P2P market, so a Indian buyer's effective cost differs from the headline dollar price.
Live market data
Current prices for the asset in this story — live, source-stamped, updated every 15 minutes.
Canary Capital’s Staking-Enabled Injective ETF Receives Nasd — questions & answers
What did Nasdaq approve?
Nasdaq approved Canary Capital’s staking-enabled Injective ETF. The product is designed to provide US investors with regulated INJ exposure and staking rewards.
How did INJ react to the ETF news?
Bitcoin Sistemi reported an approximately 6% rise following the announcement. The live snapshot shows INJ at $8.07, down 4.02% over 24 hours but up 10.93% over seven days.
What makes this ETF different from a standard INJ ETF?
The reported product includes staking functionality, allowing investors to receive staking rewards through the ETF structure rather than only holding INJ exposure.
How much is 1 Injective worth in rupee today?
About ₹849.68 at the live peer-to-peer (P2P) USDT rate, which is what Indians typically trade at — equivalent to roughly $8.17. The rupee price moves with both INJ's US-dollar price and the USDT/INR rate; use our Injective in rupee page for any amount.
Has Injective's price moved since this brief was published?
INJ is up 1.24% since this brief first published — trading at ₹772 ($8.17) now versus ₹763 ($8.07) at publication. Token Times re-checks this figure against CoinGecko and Binance every 15 minutes.
Which outlets reported this story?
This is an original Token Times brief that synthesises reporting from Bitcoin Sistemi, TronWeekly, with the key figures cross-checked for agreement across them. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original Token Times brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.